Everything we know about the Recon, a fully electric off-road SUV that blazes a trail for an eventual electric Wrangler 4x4. Everything we know about Jeep’s new electric off-road SUV. MotorTrend ...

WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...

Enhertu has been called a breakthrough in breast cancer treatment. While it doesn’t cure HER2 breast cancer, research shows that it provides patients with more time. According to the National Library ...

A report from MoparInsiders claims Stellantis is accelerating plans for the Jeep Recon EV. The electric off-roader will allegedly enter production in Q1 2025.

Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. News release. AstraZeneca and Daiichi Sankyo. Accessed August 8, 2022.

The Jeep Wrangler has offered a partially electric model for several years now with the plug-in-hybrid 4xe.However, it will soon be joined by an all-electric alternative. Enter the Jeep Recon.Like ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Enhertu is an antibody-drug conjugate. Here’s how it treats HER2-positive and HER2-low breast cancer.